#USA #Toronto #Alamar Biosciences #AAIC 2025 #pTau

Alamar Biosciences Exhibits Innovative pTau Data at AAIC 2025

Alamar Biosciences made significant strides in the field of precision proteomics by showcasing groundbreaking data on brain-derived pTau at the Alzheimer's Association International Conference (AAIC) held from July 27 to 31, 2025, in Toronto, Canada. The company presented a series of findings highlighting the NULISA™ platform's capabilities in measuring clinically relevant biomarkers for neurodegenerative diseases.

The NULISA platform is poised to revolutionize biomarker detection with unparalleled sensitivity, specificity, and multiplex capabilities, proving critical for the diagnosis and monitoring of Alzheimer's disease and related conditions. During the conference, attendees witnessed the unveiling of meaningful clinical data first gathered using NULISA to assess pTau levels from the brain, alongside over 120 notable proteins associated with central nervous system disorders. This technology has the potential to accelerate both the early detection of Alzheimer's and therapeutic monitoring of the disease.

Insights from the Conference

Dr. Yuling Luo, Founder, Chairman, and CEO of Alamar Biosciences, expressed pride in the presentation of their pTau data as a testament to the robust sensitivity and specificity of the NULISA platform. The significance of these data points extends beyond academic curiosity—they represent a vital leap towards understanding and managing Alzheimer's disease.

The formal presentation took place on July 28, 2025, featuring collaboration with prominent experts including Professor Jonathan Schott from University College London and Dr. Cheryl Wellington from the University of British Columbia. Key insights shared during the event included:

1. Performance of Brain-Derived pTau:
The presentation highlighted findings from a birth cohort study dating back to 1946, demonstrating the new brain-derived pTau isoforms using the NULISAseq™ CNS Disease Panel 120. Remarkably, this data emphasized the new pTau markers' superior capability to predict Alzheimer's disease years before clinical diagnosis.

2. Correlations with Disease Progression:
The analysis delved into the relationships between the brain-derived pTau values and amyloid/tau PET imaging. This correlation is critical for understanding how pTau levels intersect with other biomarkers associated with Alzheimer's progression.

3. Biomarkers for Neuropathologies and Alzheimer Co-Morbidities:
Using the unique cohort of patients with autopsy-confirmed pathologies, analysis via the NULISAseq™ CNS Disease Panel 120 enabled the identification of biomarkers indicative of neuropathologies and co-morbidities associated with Alzheimer's disease.

4. Preclinical Research Insights:
Additionally, the NULISAseq™ Mouse Panel 120 illustrated its beneficial use in analyzing plasma and brain homogenate samples across various Alzheimer’s disease clinical models, reinforcing its utility in foundational research.

The Alzheimer's Association International Conference (AAIC) serves as the premier platform for exchanging insights within the scientific community focused on dementia and Alzheimer’s research. Each year, the conference attracts leading scientists, clinicians, and stakeholders, fostering collaboration and advancing the search for effective diagnostics and therapies.

To explore the complete listing of posters and presentations with NULISA data from the AAIC conference, attendees can visit the official conference website for further details.

About Alamar Biosciences, Inc.

Alamar Biosciences is a private biotechnology company dedicated to advancing precision proteomics with the goal of enhancing the earliest possible disease detection. The proprietary NULISA Platform and ARGO HT System leverage the latest genomic advancements to achieve detection sensitivity at the attomole level, significantly surpassing the sensitivity of existing protein detection technologies on the market. For more information, visit alamarbio.com.